Drug intelligence / Profile preview

methylpentynol

Development stage
Discontinued
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral, Rectal
01

Overview

Methylpentynol is a tertiary acetylenic alcohol that was widely utilized in the mid-20th century as a sedative, hypnotic, and anxiolytic agent. Introduced in the early 1950s and marketed under trade names such as Oblivon and Dormison, it was primarily indicated for the short-term management of insomnia and the relief of anxiety and tension. Its pharmacological profile is characterized by central nervous system depression; research indicates it acts by inhibiting the presynaptic release of acetylcholine at both the neuromuscular junction and ganglionic synapses, and it likely modulates GABAergic neurotransmission similarly to other sedative alcohols. While it was investigated for diverse applications, including pediatric premedication and the treatment of stuttering, it proved ineffective in treating essential tremor. Methylpentynol has largely been phased out of clinical use in favor of more potent and safer alternatives, such as benzodiazepines.

Brand names
OblivonDormisonDalgolSubcorticalumPentynAtempolRiposon
Other names
3-methylpent-1-yn-3-olMeparfynolMethylparafynol3-methyl-1-pentyn-3-ol
02

Targets

GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on methylpentynol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylpentynol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call